Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Statement: Morgantown Operations
Mylan is committed to maintaining the highest quality manufacturing standards at its facilities around the world. In support of this commitment, Mylan’s plants are regularly inspected by health authorities to ensure compliance for the various markets we serve. The U.S.
View HTML
Toggle Summary Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH , June 28, 2018 /PRNewswire/ -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the two companies will partner to commercialize a biosimilar to Enbrel® (etanercept).
View HTML
Toggle Summary Mylan Launches Generic Angiomax® Injection
- Bivalirudin for Injection is an anticoagulant intended for use with aspirin - HERTFORDSHIRE, England and PITTSBURGH , June 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a
View HTML
Toggle Summary Mylan Provides Statement on Generic Advair Diskus®
On the afternoon of June 13, 2018, we received an update from the U.S. Food & Drug Administration (“FDA”) concerning our pending approval for Generic Advair Diskus® that FDA has identified minor deficiencies to be relayed in a Complete Response Letter on June 27, 2018.  Because our Abbreviated New
View HTML
Toggle Summary Americares Honors Mylan with Power of Partnership Award
Award Presented at HDA Business and Leadership Conference STAMFORD, Conn. , June 11, 2018 /PRNewswire/ -- Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Mylan, in recognition of its outstanding commitment to
View HTML
Toggle Summary U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy Fulphila is the second FDA-approved biosimilar through the Mylan-Biocon collaboration, further
View HTML
Toggle Summary Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin® approved by FDA
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , June 1, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON ) today announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology (
View HTML
Toggle Summary Mylan to Present at Goldman Sachs 39th Annual Global Healthcare Conference
HERTFORDSHIRE, England and PITTSBURGH , June 1, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA , on Wednesday, June 13, 2018 ,
View HTML
Toggle Summary Mylan Announcement of Redemption of Certain Notes Due 2019
On May 16, 2018, Mylan N.V. and Mylan Inc., an indirect wholly owned subsidiary of Mylan N.V., delivered notices to The Bank of New York Mellon, as trustee (the “Trustee”), notifying the Trustee of their election to redeem the following series of notes on June 15, 2018 (the “Redemption Date”):
View HTML
Toggle Summary Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE
Collaboration aims to demystify STEM and broaden its perceived application Program will leverage 4-H infrastructure and WVU STEM outreach, reaching every county in West Virginia Mylan commits a $5 million charitable contribution over 10 years to empower West Virginia children to be Curious, Active,
View HTML